Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

10.21037/tlcr-22-661

Saved in:

Bibliographic Details
Main Authors:	Ma, Jun, Tan, Sze Huey, Yin, Daniel Xing Cheng, Tran, Nguyen Tuan Anh, San Tan, Gek, Lai, Gillianne Geet Yi, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Rajasekaran, Tanujaa, Tan, Eng-Huat, Lim, Tony Kiat Hon, Tan, Daniel Shao-Weng, Lim, Darren Wan-Teck, Ng, Quan Sing, Tan, Wan Ling
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	AME PUBLISHING COMPANY 2024
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Respiratory System MUTATIONS AFATINIB NSCLC TKI TECHNOLOGIES AZD9291
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/248897
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

TARGETING THE PIK3 PATHWAY IN NON-SMALL CELL LUNG CANCER
by: DANIEL TAN SHAO WENG
Published: (2017)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
by: Chua, Khi Pin, et al.
Published: (2024)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022)

Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with egfr tki and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells
by: Dyrstad, Sissel E., et al.
Published: (2022)

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021)

Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure
by: Saw, Stephanie PL, et al.
Published: (2024)

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
by: Chang, Gee-Chen, et al.
Published: (2022)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

HAK MENDAHULU NEGARA ATAS PELUNASAN UTANG PAJAK TERHADAP PEMEGANG JAMINAN KEBENDAAN
by: SUKMA PUSPITA AZIZ ABDILLAH, 031724253021
Published: (2019)

Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report
by: Boongird A.
Published: (2023)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy
by: Limviphuvadh, Vachiranee, et al.
Published: (2018)

Phát hiện đột biến T790M thứ phát trên gen EGFR ở bệnh nhân ung thư phổi không tế bào nhỏ kháng thuốc điều trị đích
by: Trần, Quốc Đạt, et al.
Published: (2020)

EXPLORING TARGETED AND NON-TARGETED APPROACHES IN THE DEVELOPMENT OF ANTI-FIBROTIC THERAPY FOR LIVER FIBROSIS
by: SOH KAR LING CARRIE
Published: (2017)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)
by: Tan, Wan-Ling, et al.
Published: (2022)

SRSF1-MEDIATED TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKAEMIA
by: SINNAKANNU JOANNA RAJESWARY
Published: (2018)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014)

CHARACTERIZING CISPLATIN-RESISTANT NSCLC CELLS AND IDENTIFYING TRAIL AS A POTENTIAL SECOND-LINE THERAPY IN REFRACTORY CANCER CELLS
by: SEAH BEE KEE SERENA
Published: (2013)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
by: Tan, P.-T, et al.
Published: (2020)

Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
by: Tan, E.-H., et al.
Published: (2014)

Determinan Penggunaan Pelayanan Kesehatan Maternitas Pada Ibu Usia 15-24 Tahun Di Indonesia
by: Mabda Novalia Istafa
Published: (2019)

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
by: Shimamura, T, et al.
Published: (2020)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
by: Lai, Gillianne GY, et al.
Published: (2024)

The IκB kinase inhibitor ACHP targets the STAT3 signaling pathway in human non-small cell lung carcinoma cells
by: Lee, J.H., et al.
Published: (2021)

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
by: Zhu, Viola W., et al.
Published: (2022)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, S, et al.
Published: (2020)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
by: Byoung Chul Cho, et al.
Published: (2018)

REGULATION OF AMPK ACTIVATION AND ITS ROLE IN CELL DEATH INDUCED BY GLUCOSE STARVATION IN LKB1-MUTANT HUMAN LUNG CANCER CELLS
by: REN YI
Published: (2019)

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
by: Suriya U.
Published: (2023)

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer
by: Thanyanan Reungwetwattana, et al.
Published: (2019)

Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes
by: Yin, Xin, et al.
Published: (2024)

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
by: Popat S.
Published: (2023)

Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity
by: Zhang, X., et al.
Published: (2021)

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
by: Soo, R.A., et al.
Published: (2014)

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
by: Nokihara, H, et al.
Published: (2022)

LRG1 promotes metastatic dissemination of melanoma through regulating EGFR/STAT3 signalling
by: Kwan, Yuet Ping, et al.
Published: (2021)

Lrg1 promotes metastatic dissemination of melanoma through regulating egfr/stat3 signalling
by: Kwan, Yuet Ping, et al.
Published: (2022)